[Placebo effect and arterial pressure]. / Effetto placebo e pressione arteriosa.

The aim of the present single blind study was the assessment of the effect of placebo on office (OBP) and 24-hour ambulatory (ABP) blood pressure in patients with mild and moderate essential hypertension (WHO stage I). Ten patients (6 males, 4 females, age 51 +/- 9 years) underwent both OBP and ABP measurements at the beginning and the end of a 2-week placebo treatment. The comparison of the results of the first (OBP 156/100 +/- 15/6 mmHg, day ABP 155/96 +/- 12/7 mmHg, night ABP 139/81 +/- 21/10 mmHg) and the second sets of measurements (OBP 152/98 +/- 22/7 mmHg, day ABP 147/90 +/- 15/7 mmHg, night ABP 134/79 +/- 18/7 mmHg) did not show a statistically significant drop in OBP and night ABP, while there was a statistically significant (p < 0.05) decrease in day ABP. Thus, the effect of placebo can influence day ABP measurements, even when OBP is not decreased by placebo administration. Possible explanations involve alerting reactions to the first ABP monitorings in selected patients with mild and even moderate hypertension.

[Influence of antihypertensive therapy on the "white coat effect"]. / Influenza della terapia antipertensiva sull "effetto camice".

The aim of this study was to evaluate the alarm reaction when hypertensive patients either receiving or not receiving drug therapy have their blood pressure measured (the so-called "White coat effect"). A group of 64 patients (38 males and 26 females, mean age 52 +/- 11 years, OMS stage I-II) was studied. Twenty-three patients were not receiving antihypertensive therapy, 41 patients were regularly taking antihypertensive therapy prescribed by their own doctors. Non-invasive monitoring of arterial pressure (AP) and heart rate (HR) was carried out in all patients. The following parameters were examined in this study: mean of 3 measurements of AP and HR before monitoring (CAP, CHR), daily mean of AP and HR monitoring (MAP, MHR). The following results were obtained: 1) non-treated patients, CAP 157/108 +/- 19/11 mmHg, CHR 83 +/- 11 b/min, MAP 155/100 +/- 20/7 mmHg, MHR 76 +/- 7 b/min; 2) treated patients, CAP 151/96 +/- 21/16 mmHg, CHR 73 +/- 16 b/min, MAP 142/86 +/- 15/12 mmHg, MHR 70 +/- 10 b/min. The two-tailed "t"-test for paired data showed a statistically significant difference (p < 0.001) between diastolic CAP and diastolic MAP in both groups of patients. Systolic CAP was significantly greater than systolic MAP in treated patients (p < 0.01), whereas CHR was significantly higher than MHR in non-treated patients (p < 0.001). These data demonstrate that the alarm reaction to measuring blood pressure is present in both treated and non-treated hypertensive patients. Antihypertensive treatment appears to lessen the chronotropic but not the pressure response to measurement of AP in a hospital setting.

PET with radiolabeled aminoacid.

Since the clinical introduction of FDG, neuroimaging has been the first area of PET application in oncology. Later, while FDG-PET became progressively a key imaging modality in the management of the majority of malignancies outside the brain, its neuro-oncologic indications faced some limitations because of the unfavourable characteristics of FDG as brain tumor-seeking agent. PET applications in neuro-oncology have received new effectiveness by the advent of positron-emission labelled amino acids, so that it has been coined the term "Amino acid PET" to differentiate this imaging tool from FDG-PET. Radiolabeled amino acids are a very interesting class of PET tracers with great diagnostic potential in neuro-oncology because of their low uptake in normal brain and, conversely, high uptake in most brain tumors including low-grade gliomas. The present article surveys the results obtained using L-[methyl-11C]Methionine (MET), that has been the ancestor of PET amino acid tracers and is still the most popular amino acid imaging modality in oncology, and stresses the important role that this diagnostic modality can play in the evaluation of brain tumors. However, the use of MET is restricted to PET centers with an in-house cyclotron and radiochemistry facility, because of the short half-life (20 min) of 11C. The promising results of MET have stimulated the development of 18F-labelled aminoacid tracers, particularly O-(2-18F-fluoeoethyl1)-L-tyrosine (FET), that has the same properties of MET and, thanks to the longer half-life of 18F (about 110 min), allows a distribution strategy from a production tracer site to user satellite PET centers. Considering a more widespread use of Amino acid PET, together with the recent development of integrated PET-MRI imaging systems, and the oncoming clinical validation of other interesting PET tracers, i.e. FMISO or 18F-FAZA for hypoxia imaging and FLT for tumor proliferation imaging, it can be reasonably expected that metabolic imaging with PET is close to becoming a key diagnostic modality in the management of brain tumors, as has already been for Total Body FDG-PET/CT in extra-brain oncology.